Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18741022 | HETEROARYL-THIO-SUBSTITUTED PYRONES | June 2024 | August 2025 | Allow | 14 | 1 | 1 | Yes | No |
| 18678198 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | May 2024 | October 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18529117 | SALTS AND CRYSTAL FORMS OF GABA-A POSITIVE ALLOSTERIC MODULATOR | December 2023 | May 2025 | Allow | 17 | 1 | 0 | No | No |
| 18385766 | COMPOSITIONS AND DOSAGE FORMS FOR TREATMENT OF HPV INFECTION AND HPV-INDUCED NEOPLASIA | October 2023 | December 2024 | Allow | 13 | 2 | 0 | Yes | No |
| 18385778 | TREATMENT OF HPV-INDUCED NEOPLASIA | October 2023 | January 2025 | Abandon | 15 | 1 | 1 | No | No |
| 18267416 | PHOSPHORUS COMPOUNDS AND METHODS THEREOF | June 2023 | February 2026 | Allow | 32 | 0 | 1 | No | No |
| 18033114 | CIS-PARA-SUBSTITUTED CYCLOHEXYLAMINONITRILE SALT, PREPARATION METHOD THEREFOR AND USE THEREOF, AND METHOD FOR PREPARING PESTICIDE USING SAME | April 2023 | February 2026 | Allow | 33 | 0 | 1 | Yes | No |
| 18301025 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | April 2023 | December 2024 | Allow | 20 | 3 | 0 | Yes | No |
| 18029962 | SOLID STATE FORMS OF RESMETIROM | April 2023 | January 2026 | Allow | 33 | 0 | 1 | No | No |
| 18116557 | OXYSTEROLS AND METHODS OF USE THEREOF | March 2023 | June 2024 | Allow | 16 | 1 | 1 | No | No |
| 18043740 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | March 2023 | December 2025 | Allow | 33 | 1 | 0 | No | No |
| 18041880 | Novel ruthenium complexes, methods of their preparation and application thereof in olefin cross metathesis | February 2023 | February 2026 | Allow | 36 | 2 | 0 | Yes | No |
| 18019070 | PROCESS FOR PREPARATION OF MESOTRIONE AND ITS INTERMEDIATES | January 2023 | August 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 18018822 | COLD MEDICINE AND ANTIVIRAL MEDICINE | January 2023 | February 2026 | Allow | 37 | 1 | 1 | Yes | No |
| 18007370 | METHOD FOR PRODUCING 2-(HALOGENATED METHYL)NAPHTHALENE AND 2-NAPHTHYL ACETONITRILE | January 2023 | December 2025 | Allow | 34 | 2 | 0 | Yes | No |
| 18002037 | THYROMIMETICS | December 2022 | September 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 18054921 | METHODS FOR PREPARING A BORON DIPYRROMETHENE (BODIPY) DERIVATIVE AND APPLICATIONS THEREOF | November 2022 | January 2025 | Allow | 26 | 1 | 1 | No | No |
| 17922140 | METHOD FOR PREPARING BRIVARACETAM AND INTERMEDIATE THEREOF | October 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17996321 | Benzimidazole derivatives | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | Yes | No |
| 17964489 | PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | October 2022 | May 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 17929597 | GPX4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING GPX4-MEDIATED DISEASES | September 2022 | August 2025 | Allow | 35 | 2 | 0 | Yes | No |
| 17802994 | HYDROBORATION-OXIDATION PROCESS | August 2022 | December 2025 | Allow | 40 | 1 | 0 | No | No |
| 17887289 | NUCLEOTIDE ANALOGS AND USES THEREOF | August 2022 | August 2025 | Allow | 36 | 0 | 1 | No | No |
| 17788284 | ICAN DERIVATIVES FOR ANTIFUNGAL USE | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17783287 | CANNABINOID DERIVATIVES | June 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17780344 | METHOD FOR PRODUCING MAXACALCITOL, AND INTERMEDIATE THEREFOR | May 2022 | March 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17780465 | NOVEL THYROMIMETICS | May 2022 | April 2025 | Allow | 35 | 1 | 0 | No | No |
| 17779678 | LOBINALINE N-OXIDES AS POSITIVE ALLOSTERIC MODULATORS OF THE DOPAMINE TRANSPORTER WITH POTENTIAL VALUE IN THE TREATMENT OF SUBSTANCE ABUSE DISORDERS | May 2022 | May 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17755983 | MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF | May 2022 | November 2025 | Allow | 42 | 2 | 0 | Yes | No |
| 17775985 | NOVEL SUBSTITUTED 6- MEMBERED HETEROARYL PIPERIDINYL ETHANONES | May 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17773171 | LOCAL ANESTHETICS WITH SELECTIVE-SENSORY NERVE BLOCKADE | April 2022 | June 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17773349 | CINNAMIC AMIDE DERIVATIVE HAVING FXR ACTIVATING EFFECT, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT, AND METHOD FOR PREPARING THE SAME | April 2022 | October 2025 | Allow | 41 | 1 | 1 | No | No |
| 17770690 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | April 2022 | June 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17770681 | NICOTINAMIDE COMPOUND AND HERBICIDAL COMPOSITION COMPRISING COMPOUND | April 2022 | October 2025 | Allow | 42 | 1 | 1 | No | No |
| 17770502 | ANALOGUES OF N-ACYL-HOMOSERINE LACTONES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | April 2022 | May 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17770242 | AGENT FOR PROMOTING ODONTOBLAST PROPAGATION AND DIFFERENTIATION | April 2022 | September 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17761984 | CARBONATE CONTAINING LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | March 2022 | December 2025 | Allow | 45 | 0 | 1 | Yes | No |
| 17761273 | THIAZOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | March 2022 | September 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17636788 | USE OF A NEUTROPHIL ELASTASE INHIBITOR IN LUNG DISEASE | February 2022 | March 2026 | Abandon | 48 | 0 | 1 | No | No |
| 17635710 | SALT | February 2022 | February 2026 | Abandon | 48 | 1 | 1 | No | No |
| 17632751 | NEO-BAVAISOFLAVONE AND COMPOSITIONS THEREOF AND THEIR USE AS PESTICIDES | February 2022 | November 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17630105 | HETEROARYL-SUBSTITUTED PYRAZOLO-PYRIDINE PROTEIN KINASE INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | January 2022 | February 2026 | Allow | 49 | 1 | 0 | No | No |
| 17581178 | SELECTIVE DIHYDROPYRROLOPYRIMIDINE JAK2 INHIBITORS | January 2022 | June 2025 | Allow | 40 | 1 | 0 | No | No |
| 17578624 | MATERIAL FOR FORMING ORGANIC FILM, SUBSTRATE FOR MANUFACTURING SEMICONDUCTOR DEVICE, METHOD FOR FORMING ORGANIC FILM, PATTERNING PROCESS, AND COMPOUND FOR FORMING ORGANIC FILM | January 2022 | January 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17627831 | HERBICIDAL COMPOUNDS | January 2022 | June 2025 | Allow | 41 | 1 | 0 | No | No |
| 17627857 | COMBINATION THERAPY FOR CANCER TREATMENT | January 2022 | October 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17627530 | SUBSTITUTED PYRIDAZINONES AS HERBICIDES | January 2022 | June 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17623461 | SYNTHESIS OF CHOLESTEROL AND VITAMIN D3 FROM PHYTOSTEROLS | December 2021 | January 2026 | Allow | 49 | 1 | 1 | Yes | No |
| 17562976 | HYDRAZONE AMIDE DERIVATIVE AND APPLICATION THEREOF IN PREPARATION OF MEDICAMENTS FOR PREVENTING AND TREATING ALOPECIA | December 2021 | August 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17561055 | ANDROGEN RECEPTOR BINDING MOLECULE AND USE THEREOF | December 2021 | July 2024 | Allow | 31 | 2 | 0 | Yes | No |
| 17621075 | IMPROVED, COST EFFECTIVE PROCESS FOR SYNTHESIS OF VITAMIN D3 AND ITS ANALOGUE CALCIFEDIOL FROM ERGOSTEROL | December 2021 | January 2026 | Allow | 49 | 1 | 1 | Yes | No |
| 17544303 | CYCLIN DEPENDENT KINASE INHIBITORS | December 2021 | March 2025 | Allow | 39 | 0 | 1 | No | No |
| 17614797 | COMPOUND FOR INHIBITING RORyt ACTIVITY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | November 2021 | April 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17595820 | FUSED HETEROCYCLIC DERIVATIVES | November 2021 | April 2025 | Allow | 41 | 1 | 1 | No | No |
| 17611540 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | November 2021 | September 2024 | Allow | 34 | 0 | 0 | Yes | No |
| 17608392 | INHIBITING TRABID | November 2021 | March 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17607605 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | October 2021 | July 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17607153 | A STABLE FORMULATION OF ARYLSULFONYLPROPENENITRILES | October 2021 | August 2025 | Allow | 45 | 3 | 1 | Yes | No |
| 17452507 | CRYSTALLINE FORMS OF A PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR | October 2021 | August 2024 | Allow | 33 | 1 | 0 | No | No |
| 17452025 | COMPOUNDS, COMPOSITIONS AND METHODS | October 2021 | November 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17501701 | METHODS OF USE FOR TRISUBSTITUTED BENZOTRIAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS | October 2021 | January 2025 | Allow | 39 | 1 | 1 | No | No |
| 17601855 | PHARMACEUTICAL FORMULATIONS CONTAINING P2Y14 ANTAGONISTS | October 2021 | July 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17600408 | TRIAZOLOPYRIMIDINES BASED ON THYMINE NUCLEOBASE AND METHODS FOR PRODUCING THEM | September 2021 | April 2025 | Allow | 43 | 2 | 1 | No | No |
| 17599931 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | September 2021 | September 2025 | Abandon | 48 | 3 | 1 | No | No |
| 17593372 | SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS | September 2021 | October 2025 | Allow | 49 | 1 | 1 | No | No |
| 17439324 | EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17437364 | USE OF A NEMATICIDE COMPOSITION | September 2021 | June 2025 | Allow | 45 | 2 | 0 | No | No |
| 17436821 | COMPOUNDS HAVING BOTH EFFECTS OF BET BROMODOMAIN PROTEIN INHIBITION AND PD-L1 GENE REGULATION | September 2021 | March 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17462800 | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE | August 2021 | December 2024 | Allow | 40 | 1 | 0 | No | No |
| 17411343 | PHARMACEUTICAL COMPOUNDS | August 2021 | June 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17409834 | COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING A DEMENTIA | August 2021 | December 2024 | Allow | 40 | 3 | 1 | Yes | No |
| 17409836 | COMPOSITIONS AND METHODS OF TREATMENT FOR NEUROLOGICAL DISORDERS COMPRISING MOTOR NEURON DISEASES | August 2021 | December 2024 | Allow | 40 | 3 | 1 | No | No |
| 17432089 | Novel compounds and their uses as thyroid hormone receptor agonists | August 2021 | February 2025 | Allow | 42 | 1 | 1 | No | No |
| 17428600 | METHODS OF INDUCING AUTOPHAGY USING COUMARIN DERIVATIVES AND RELATED COMPOUNDS | August 2021 | February 2026 | Allow | 55 | 1 | 1 | No | No |
| 17427070 | HYDRAZIDE COMPOUND AND KINASE INHIBITOR | July 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17423151 | SUBSTITUTED POLYCYCLIC CARBOXYLIC ACIDS, ANALOGUES THEREOF, AND METHODS USING SAME | July 2021 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17371001 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | July 2021 | February 2025 | Allow | 43 | 2 | 1 | No | No |
| 17370216 | MODULATORS OF PIN1 ACTIVITY AND USES THEREOF | July 2021 | September 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17419837 | INHIBITORS OF CGAS ACTIVITY AS THERAPEUTIC AGENTS | June 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17418693 | ETHYLENEDIAMINE COMPOUND AND USE THEREOF | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17416971 | CYCLIN-DEPENDENT KINASE INHIBITORS | June 2021 | May 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17416741 | Chemical Compound Manufacture, New Salt Form, And Therapeutic Uses Thereof | June 2021 | February 2025 | Allow | 44 | 4 | 1 | No | No |
| 17413425 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | June 2021 | December 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17312810 | CROMOLYN ESTERS AND USES THEREOF | June 2021 | April 2025 | Allow | 46 | 2 | 1 | No | No |
| 17311974 | 1-(2,6-DIAZASPIRO[3.3]HEPTAN-6-YL)-5,6-DIHYDRO-4H-BENZO[F][1,2,4]TRIAZOLO[4,3-A][1,4]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS VASOPRESSIN ANTAGONISTS FOR THE TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | June 2021 | July 2024 | Allow | 38 | 1 | 0 | No | No |
| 17299930 | SYNERGISTIC COMPOSITIONS COMPRISING R-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES AND S-2-(SUBSTITUTED-SULFONYL)-HEXAHYDRO-PYRROLO[1,2-A]PYRAZIN-6(2H)-ONES IN A NON-RACEMIC RATIO | June 2021 | September 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17311293 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | June 2021 | September 2024 | Allow | 40 | 1 | 1 | No | No |
| 17311287 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | June 2021 | September 2024 | Allow | 40 | 1 | 1 | No | No |
| 17337570 | INHIBITORS OF ERK NUCLEAR TRANSLOCATION | June 2021 | January 2025 | Allow | 44 | 1 | 1 | No | No |
| 17337547 | SYNTHESIS OF TRANS-8-CHLORO-5-METHYL-1 -[4-(PYRIDIN-2-YLOXY)-CYCLOHEXYL]-5,6-DIHYDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENE AND CRYSTALLINE FORMS THEREOF | June 2021 | July 2025 | Allow | 49 | 1 | 1 | No | No |
| 17335440 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | June 2021 | January 2026 | Abandon | 55 | 2 | 1 | No | No |
| 17296836 | SALT AND CRYSTALLINE FORM OF FUROPYRIMIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | May 2021 | October 2024 | Allow | 41 | 1 | 1 | No | No |
| 17243120 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | April 2021 | December 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17289418 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADENOMYOSIS AND RECTOVAGINAL ENDOMETRIOSIS | April 2021 | August 2024 | Allow | 40 | 1 | 1 | No | No |
| 17241906 | AMORPHOUS SOLID DISPERSION COMPRISING 6-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)NICOTINAMIDE | April 2021 | August 2024 | Allow | 40 | 1 | 1 | No | No |
| 17235321 | PESTICIDALLY ACTIVE POLYCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | April 2021 | June 2024 | Allow | 38 | 0 | 1 | No | No |
| 17283613 | BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS | April 2021 | July 2025 | Allow | 51 | 4 | 0 | Yes | No |
| 17282547 | COMPOSITION FOR PREVENTION OR TREATMENT OF MACULAR DEGENERATION | April 2021 | October 2024 | Allow | 43 | 2 | 1 | No | No |
| 17204206 | PARG INHIBITORY COMPOUNDS | March 2021 | June 2024 | Allow | 39 | 1 | 1 | No | No |
| 17271950 | CHRONIC NIGHTLY DOSING OF LASMIDITAN FOR MIGRAINE PREVENTION | February 2021 | May 2024 | Allow | 38 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHENG, KAREN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHENG, KAREN works in Art Unit 1623 and has examined 196 patent applications in our dataset. With an allowance rate of 87.8%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 23 months.
Examiner CHENG, KAREN's allowance rate of 87.8% places them in the 67% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by CHENG, KAREN receive 1.13 office actions before reaching final disposition. This places the examiner in the 12% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CHENG, KAREN is 23 months. This places the examiner in the 85% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +17.1% benefit to allowance rate for applications examined by CHENG, KAREN. This interview benefit is in the 58% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 34.1% of applications are subsequently allowed. This success rate is in the 75% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 57.7% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 71.9% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 10.2% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.